Abstract:Background: The blood-brain barrier (BBB) describes the brain's highly specialized capillaries, which form a dynamic interface that maintains central nervous system (CNS) homeostasis. The BBB supports the CNS, in part, by preventing the entry of potentially harmful circulating molecules into the brain. However, this specialized function is challenging for the development of CNS therapeutics. Several strategies to facilitate drug delivery into the brain parenchyma via disruption of the BBB have been proposed. Bradykinin has proven effective in disrupting mechanisms across the blood-tumor barrier. Unfortunately, bradykinin has limited therapeutic value because of its short half-life and the undesirable biological activity elicited by its active metabolites. Objective: To evaluate NG291, a stable bradykinin analog, with selective agonist activity on the bradykinin-B2 receptor and its ability to disrupt the BBB transiently. Methods: Sprague Dawley rats and CD-1 mice were subjected to NG291 treatment (either 50 or 100 μg/kg, intravenously). Time and dose-dependent BBB disruption were evaluated by histological analysis of Evans blue (EB) extravasation. Transcellular and paracellular BBB leakage were assessed by infiltration of 99mTc-albumin (66.5 KDa) and 14C-sucrose (340 Da) radiolabeled probes into the brains of CD-1 mice treated with NG291. NG291 influence on P-glycoprotein (P-gp) efflux pump activity was evaluated by quantifying the brain accumulation of 3H-verapamil, a known P-gp substrate, in CD-1 mice. Results: NG291-mediated BBB disruption was localized, dose-dependent, and reversible as measured by EB extravasation. 99mTc-albumin leakage was significantly increased by 50 μg/kg of NG291, whereas 100 μg/kg of NG291 significantly augmented both 14C-sucrose and 99mTc-albumin leakage. NG291 enhanced P-gp efflux transporter activity and was unable to increase brain uptake of the P-gp substrate pralidoxime. NG291 did not evoke significant short-term neurotoxicity, as it did not increase brain water content, the number of Fluoro-Jade C positive cells, or astrocyte activation. Conclusion: Our findings strongly suggest that NG291 increases BBB permeability by two different mechanisms in a dose-dependent manner and increases P-gp efflux transport. This increased permeability may facilitate the penetration into the brain of therapeutic candidates that are not P-gp substrates.

Bradykinin increases the permeability of the blood-tumor barrier by the caveolae-mediated transcellular pathway

The Bradykinin B2 Receptor Mediates Hypoxia/reoxygenation Induced Neuronal Cell Apoptosis Through the ERK1/2 Pathway

In Vitro Effect of TNF-α Expression Induced by Bradykinin in Glioma Cells on the Blood-Tumor Barrier

Study of relation between bradykinin-induced blood-tumor barrier opening and TNF-α/MAPK/NF-κB

Increase in Blood–Brain Barrier Permeability is Modulated by Tissue Kallikrein via Activation of Bradykinin B1 and B2 Receptor-Mediated Signaling

STEM-26. BLOOD-TUMOR BARRIER IS COMPOSED OF MECHANOSENSING TUMOR CELLS THAT MASK THERAPEUTIC VULNERABILITY

Effect of Retro-Inverso Isomer of Bradykinin on Size-Dependent Penetration of Blood-Brain Tumor Barrier

Bradykinin protects against brain microvascular endothelial cell death induced by pathophysiological stimuli

Caveolae Targeting and Regulation of Large Conductance Ca2+-activated K+ Channels in Vascular Endothelial Cells

Bradykinin Promotes Proliferation, Migration, and Invasion of Cervical Cancer Cells Through STAT3 Signaling Pathways

Serum Bradykinin Levels As a Diagnostic Marker in Cervical Cancer with a Potential Mechanism to Promote VEGF Expression Via BDKRB2

Bradykinin B1 Receptor Affects Tumor-Associated Macrophage Activity and Glioblastoma Progression

Enhancement of bradykinin-induced relaxation by focal brain ischemia in the rat middle cerebral artery: Receptor expression upregulation and activation of multiple pathways

Mechanism of Non-Capacitative Ca2+ Influx in Response to Bradykinin in Vascular Endothelial Cells.

Effects of Bradykinin on TGF‑β1‑induced Epithelial‑mesenchymal Transition in ARPE‑19 Cells.

Bradykinin Inhibits the Transient Outward K+ Current in Mouse Schwann Cells Via the Camp/Pka Pathway

Pharmacological and functional characterization of bradykinin receptors in rat cultured vascular smooth muscle cells

Bradykinin, as a Reprogramming Factor, Induces Transdifferentiation of Brain Astrocytes into Neuron-like Cells

The Bradykinin B2 Receptor Agonist (NG291) Causes Rapid Onset of Transient Blood-Brain Barrier Disruption Without Evidence of Early Brain Injury

Blockade of Bradykinin B2 Receptor More Effectively Reduces Postischemic Blood–brain Barrier Disruption and Cytokines Release Than B1 Receptor Inhibition

Role of caveolin-1 in the biology of the blood-brain barrier.